News
A team of scientists has uncovered the remarkable potential of a human antibody, mAb 3A6, in fighting Ebola virus infections.
Clinical Trials Arena on MSN3d
Akeso and Summit notch another Phase III win with their Keytruda competitorAkeso Pharmaceuticals and Summit Therapeutics have reported that their PD-1/VEGF bispecific antibody has met the primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback